Mouse IL-28A/IFN-lambda 2 Antibody

Catalog #: MAB4635
1 Citation Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB4635
MAB4635-SP

IL‑28A/IFN‑ lambda 2 Inhibition of EMCV-induced Cytopathy and Neutralization by Mouse IL‑28A/IFN‑ lambda 2 Antibody.

1 Image

Product Details

Citations (1)

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Mouse IL-28A/IFN-lambda 2 Antibody Summary

Species Reactivity

Mouse

Specificity

Detects mouse IL-28A/IFN-lambda 2 in direct ELISAs. In direct ELISAs, approximately 50% cross-reactivity with recombinant mouse IL-28B and no cross-reactivity with recombinant human (rh) IL-28A, rhIL-28B, or rhIL-29 is observed.

Source

Monoclonal Rat IgG_2B Clone # 625616

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

Mouse myeloma cell line NS0-derived recombinant mouse IL-28A/IFN-lambda 2
Asp20-Val193
Accession # NP_001019844

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Applications

Recommended Concentration

Sample

Neutralization

Measured by its ability to neutralize IL‑28A/IFN‑ lambda 2 inhibition of EMCV-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line. Sheppard, P. et al. (2003) Nat. Immunol. 4:63. The Neutralization Dose (ND₅₀) is typically 2-10 µg/mL in the presence of 20 ng/mL Recombinant Mouse IL‑28A/IFN‑ lambda 2.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization

View Larger

IL‑28A/IFN‑ lambda 2 Inhibition of EMCV-induced Cytopathy and Neutralization by Mouse IL‑28A/IFN‑ lambda 2 Antibody. Recombinant Mouse IL-28A (Catalog # 4635-ML) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line), as measured by Resazurin. Inhibition of EMCV activity elicited by Recombinant Mouse IL-28A (20 ng/mL) is neutralized (green line) by increasing concentrations of Mouse IL-28A Monoclonal Antibody (Catalog # MAB4635). The ND₅₀ is typically 2-10 µg/mL.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Sterile PBS to a final concentration of 0.5 mg/mL.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IL-28A/IFN-lambda 2

IL-28A (also named interferon-lambda 2, IFN-lambda 2), IL-28B (IFN-lambda 3) and IL-29 (IFN-lambda 1) are type III interferons that are class II cytokine receptor ligands (1‑4). They are distantly related to members of the IL-10 family and type I IFN family (1‑4). Mouse IL-28A cDNA encodes a 193 amino acid (aa) protein with a 19 aa signal peptide and a 174 aa mature protein that lacks N-glycosylation sites. Mature mouse IL-28A shares 81% and 66% aa sequence identity with rat and human IL-28A, respectively, and functions across species (5). Mouse IL-28A and IL-28B share 97% aa identity; the mouse lacks a functional IL-29 gene (4). Type III interferons are widely expressed, but are mainly produced by antigen presenting cells in response to viruses and double-stranded RNA that interact with Toll-like receptors or RIG-1 family helicases (2‑6). They signal through a widely expressed receptor that is a heterodimer of the IL-10 receptor beta (IL-10 R beta ) and IL-28 receptor alpha (IL-28 R alpha ; also called IFN-lambda R1) (2, 3, 7, 9). Interaction of either type I or type III IFNs with their receptors activates similar pathways, including JAK tyrosine kinase activation, STAT phosphorylation and formation of the IFN-stimulated regulatory factor 3 (ISGF-3) transcription factor complex (1‑3). Both type I and III IFNs induce antiviral activity and upregulate MHC class I antigen expression (2‑6). Cell lines responsive to type III IFNs are also responsive to type I IFNs, but in general, higher concentrations of type III IFNs are needed for similar in vitro responses (8). In vivo, however, type III IFNs enhance levels of IFN-gamma in serum, suggesting that the robust antiviral activity of type III IFNs may stem in part from activation of the immune system (5, 7). Anti-proliferative and antitumor activity in vivo has also been shown for type III IFNs (9‑11).

References

Chen, Q. et al. (2006) Vitam. Horm. 74:207.
Sheppard, P. et al. (2003) Nat. Immunol. 4:63.
Kotenko, S.V. et al. (2003) Nat. Immunol. 4:69.
Bartlett, N.W. et al. (2005) J. Gen. Virol. 86:1589.
Ank, N. et al. (2006) J. Virol. 80:4501.
Onoguchi, K. et al. (2007) J. Biol. Chem. 282:7576.
Siebler, J. et al. (2007) Gastroenterology 132:358.
Meager, A. et al. (2005) Cytokine 31:109.
Lasfar, A. et al. (2006) Cancer Res. 66:4468.
Sato, A. et al. (2006) J. Immunol. 176:7686.
Zitzmann, K. et al. (2006) Biochem. Biophys. Res. Commun. 344:1334.

Long Name

Interleukin 28A

Entrez Gene IDs

282616 (Human)

Alternate Names

interleukin-28A; IFN-lambda 2; IL28A; IL-28A; interferon, lambda 2

Product Datasheets

Product Datasheet

COA

SDS

Related Research Areas

Citation for Mouse IL-28A/IFN-lambda 2 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

1 Citation: Showing 1 - 1